All In Biotech

Drug Trial Radar · NCT00089700

TNX-355 With Optimized Background Therapy (OBT) in Treatment-Experienced Subjects With HIV-1

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Three-Arm Study of the Anti-CD4 Monoclonal Antibody TNX-355 With Optimized Background Therapy in Treatment-Experienced Subjects Infected With HIV-1

Last checked: Nov 20, 2026Latest source record: Jun 24, 2005 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

80

Actual

Start

Mar 2004

Primary completion

Not stated

Sponsor

Lead sponsor
TanoxIndustry
Sponsor type
Industry
First posted
Aug 12, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 48-week study to compare TNX-355 plus OBT to placebo plus OBT in HIV subjects. You must have a stable viral load of at least 10,000 copies/ml, been treated with highly active antiretroviral therapy (HAART) for at least 6 months, be triple class experienced, and presently failing or have failed a HAART regimen. Subjects will receive infusions every week for 8 weeks, then every two weeks.

Conditions

  • HIV Infections

Interventions

  • TNX-355Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

15 sites in 3 countries. Site status is shown where the registry gives one.

  • Body Positive

    Phoenix, Arizona

  • Altamed Corporation

    Los Angeles, California

  • Tower ID Medical Associates

    Los Angeles, California

  • Dupont Circle Physicians Group

    Washington D.C., District of Columbia

  • IDC Research Initiative

    Altamonte Springs, Florida

  • Bach and Godofsky

    Bradenton, Florida

  • University of Miami

    Miami, Florida

  • Comprehensive Research Institute

    Tampa, Florida

  • Brobson Lutz, MD, LLC

    New Orleans, Louisiana

  • Chase-Brexton Health Services, Inc.

    Baltimore, Maryland

  • Johns Hopkins University School of Medicine

    Baltimore, Maryland

  • University of Cincinnati Medical Center

    Cincinnati, Ohio

  • Tanox, Inc.

    Houston, Texas

  • Sunnybrook Health Science Centre

    Toronto, Ontario, Canada

  • Clinical Research Puerto Rico, Inc.

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.